Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia.
Regulation of the extracellular matrix by proteases and protease inhibitors is a fundamental biological process for normal growth, development and repair in the CNS. Matrix metalloproteinases (MMPs) and the tissue inhibitors of metalloproteinases (TIMPs) are the major extracellular-degrading enzymes. Two other enzyme families, a disintegrin and metalloproteinase (ADAM), and the serine proteases, plasminogen/plasminogen activator (P/PA) system, are also involved in extracellular matrix degradation. Normally, the highly integrated action of these enzyme families remodels all of the components of the matrix and performs essential functions at the cell surface involved in signaling, cell survival, and cell death. During the inflammatory response induced in infection, autoimmune reactions and hypoxia/ischemia, abnormal expression and activation of these proteases lead to breakdown of the extracellular matrix, resulting in the opening of the blood-brain barrier (BBB), preventing normal cell signaling, and eventually leading to cell death. There are several key MMPs and ADAMs that have been implicated in neuroinflammation: gelatinases A and B (MMP-2 and -9), stromelysin-1 (MMP-3), membrane-type MMP (MT1-MMP or MMP-14), and tumor necrosis factor-alpha converting enzyme (TACE). In addition, TIMP-3, which is bound to the cell surface, promotes cell death and impedes angiogenesis. Inhibitors of metalloproteinases are available, but balancing the beneficial and detrimental effects of these agents remains a challenge.
Candelario-Jalil
E
E
Department of Neurology, University of New Mexico Health Sciences Center, MSC10 5620, 1 University of New Mexico, Albuquerque, NM 87131-0001, USA.
Yang
Y
Y
Rosenberg
G A
GA
D000818:Animals; D015551:Autoimmunity / Q000276:immunology; D001812:Blood-Brain Barrier / Q000201:enzymology* / Q000276:immunology / Q000503:physiopathology; D001929:Brain Edema / Q000201:enzymology / Q000276:immunology / Q000503:physiopathology; D002545:Brain Ischemia / Q000201:enzymology* / Q000276:immunology / Q000503:physiopathology; D016923:Cell Death / Q000276:immunology; D004660:Encephalitis / Q000201:enzymology* / Q000276:immunology / Q000503:physiopathology; D005109:Extracellular Matrix / Q000201:enzymology*; D006801:Humans; D020782:Matrix Metalloproteinases / Q000276:immunology / Q000378:metabolism*; D009410:Nerve Degeneration / Q000201:enzymology / Q000276:immunology / Q000503:physiopathology; D019714:Tissue Inhibitor of Metalloproteinases / Q000276:immunology / Q000378:metabolism*
D019714:Tissue Inhibitor of Metalloproteinases; D020782:Matrix Metalloproteinases